ITPAgenotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response
| Autor: | Paul V. Desmond, William Sievert, Gail V. Matthews, Stuart K. Roberts, Geoffrey W. McCaughan, S. Bonanzinga, Wendy Cheng, D. Scott Bowden, Jacinta A Holmes, Vijaya Sundararajan, Rachel J. Ali, Gregory J. Dore, Kumar Visvanathan, Martin Weltman, Darrell H. G. Crawford, Alexander J. Thompson |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
education.field_of_study
medicine.medical_specialty Hepatology Anemia business.industry Ribavirin Population virus diseases Alpha interferon medicine.disease Gastroenterology digestive system diseases Telaprevir chemistry.chemical_compound ITPase activity chemistry Internal medicine Boceprevir Immunology medicine ITPA education business medicine.drug |
| Zdroj: | Hepatology. 59:2152-2160 |
| ISSN: | 0270-9139 |
| DOI: | 10.1002/hep.27022 |
| Popis: | On-treatment anemia is associated with higher sustained virological response (SVR) rates during peginterferon plus ribavirin (RBV) therapy. Inosine triphosphatase (ITPA) variants causing ITPase deficiency have been shown to protect against RBV-induced anemia. However, ITPase activity has not been associated with SVR. To study this discrepancy, we examined the relationships between ITPase activity, on-treatment anemia, SVR, and RBV levels in hepatitis C virus genotype 1 (HCV-1) patients from the CHARIOT study. ITPA genotype (rs7270101, rs1127354) was used to define ITPase activity in 546 patients. Plasma RBV levels were measured using high-performance liquid chromatography (HPLC). Relationships between ITPase activity, on-treatment hemoglobin (Hb) levels, RBV levels, and SVR were tested using regression modeling, survival analysis, and locally weighted scatterplot smoothing (LOWESS) plot analysis. Hb decline was independently associated with SVR (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text